Can we predict cytomegalovirus reactivation in critically ill patients?

Critical Care Medicine

Volumn 40, Issue 12, 2012, Pages 3313-3314

  Florescu, Diana F ^a   Kalil, Andre C ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

cytomegalovirus; interferon ?; sepsis

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15;

CRITICALLY ILL PATIENT; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EDITORIAL; HUMAN; INTENSIVE CARE UNIT; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LOAD; VIRUS REACTIVATION;

CRITICAL ILLNESS; CYTOMEGALOVIRUS; FEMALE; HUMANS; INTERFERON-GAMMA; KILLER CELLS, NATURAL; MALE; VIRUS ACTIVATION;

EID: 84870163401     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31826563a4     Document Type: Editorial

References (12)

1. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-150
2. Lünemann A, Lünemann JD, Münz C: Regulatory NK-cell functions in inflammation and autoimmunity. Mol Med 2009; 15:352-358
3. Orange JS, Ballas ZK: Natural killer cells in human health and disease. Clin Immunol 2006; 118:1-10
4. Caligiuri MA: Human natural killer cells. Blood 2008; 112:461-469
5. Venet F, Davin F, Guignant C, et al: Early assessment of leukocyte alterations at diagnosis of septic shock. Shock 2010; 34:358-363
6. Kalil AC, Florescu DF: Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit. Crit Care Med 2009; 37:2350-2358
7. Chiche L, Forel J-M, Thomas G, et al: Interferon-γ production by natural killer cells and cytomegalovirus in critically ill patients. Crit Care Med 2012; 40:3162-3169
8. Walker S, Fazou C, Crough T, et al: Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl Infect Dis 2007; 9:165-170
9. Kumar D, Chernenko S, Moussa G, et al: Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009; 9:1214-1222
10. Nebbia G, Mattes FM, Smith C, et al: Polyfunctional cytomegalovirus- specific CD4+ and pp65 CD8+ T cells protect against high-level replication after liver transplantation. Am J Transplant 2008; 8:2590-2599
11. Fleming T, Dunne J, Crowley B: Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital. J Med Virol 2010; 82:433-440
12. Solano C, Benet I, Remigia MJ, et al: Immunological monitoring for guidance of preemptive antiviral therapy for active cytomegalovirus infection in allogeneic stem-cell transplant recipients: A pilot experience. Transplantation 2011; 92:e17-e20